Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Repligen Corporation (Nasdaq: RGEN) announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical.  Repligen is the world's leading supplier of recombinant Protein A and has manufactured recombinant Protein A for GE Healthcare for more than 10 years.  This agreement provides for Repligen to continue to be a strategic supplier to GE Healthcare through 2014.  GE Healthcare sells chromatography products which incorporate Repligen's recombinant Protein A to the biopharmaceutical industry for the manufacture of monoclonal antibodies.

"We are very pleased to continue our long standing relationship with GE Healthcare," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "This agreement ensures continuity in the supply of high quality recombinant Protein A supported by our business continuity plans and quality systems that are required by the biopharmaceutical industry."

There are currently more than 25 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical development.  The worldwide revenues from this class of drug exceeded $35 billion in 2009.